This bill mandates that medical care providers review FDA medication guides with the parent, guardian, or state-designated caregiver before prescribing psychotropic drugs to minors under Medicaid. It introduces a new section, RSA 167:3-n, which defines key terms such as "psychotropic drugs," "medical care providers," and "FDA medication guides." The bill requires that a physical copy of the medication guide be provided and reviewed, detailing the FDA-identified risks, potential side effects, and adverse reactions associated with the medication. Additionally, written informed consent must be obtained from the parent, guardian, or caregiver, confirming their understanding of the information provided.

The bill also stipulates penalties for medical care providers who fail to comply with these requirements, including potential suspension of Medicaid reimbursements and reporting to the appropriate governing board. The effective date for this act is set for April 1, 2026. The fiscal note indicates that the bill will not provide funding or authorize new positions but is expected to result in increased costs to the state, estimated between $1 million to $2.5 million annually, due to the additional requirements placed on providers and the potential for increased investigations and disenrollment of non-compliant providers.